STOCK TITAN

Immunogen Inc - IMGN STOCK NEWS

Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.

Immunogen Inc (IMGN) is a clinical-stage biotechnology leader pioneering targeted cancer therapies through its proprietary antibody-drug conjugate (ADC) technology. This dedicated news hub provides investors and industry professionals with timely updates on IMGN's scientific advancements, regulatory milestones, and strategic partnerships.

Our curated collection offers immediate access to official press releases, clinical trial developments, and collaboration announcements. Users will find updates on oncology research progress, FDA interactions, and technology licensing agreements that shape IMGN's position in the biopharmaceutical landscape.

Key content types include pipeline advancements for solid tumor treatments, partnership expansions with major pharmaceutical companies, and financial disclosures. The platform serves as a reliable resource for understanding how IMGN's ADC platform addresses complex oncology challenges through precision-targeted therapeutics.

Bookmark this page for streamlined tracking of IMGN's scientific and corporate developments. Combine these updates with Stock Titan's analysis tools to monitor the company's progress in transforming cancer treatment paradigms.

Rhea-AI Summary
IMGN: ImmunoGen Announces Departure of Chief Medical Officer and Successor Appointment. Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer, is stepping down to pursue new opportunities outside of ImmunoGen. Michael Vasconcelles, MD, Executive Vice President, Research, Development, and Medical Affairs, will assume the role of Chief Medical Officer. The announcement highlights Dr. Berkenblit's significant contributions to ImmunoGen's pivotal development program for ELAHERE (mirvetuximab soravtansine-gynx) and the accelerated approval for patients with platinum-resistant ovarian cancer. The press release also emphasizes the company's continued advancement of their clinical pipeline of next-generation ADCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
none
-
Rhea-AI Summary
ImmunoGen, Inc. reported net sales of $77.4 million in Q2 for their therapy ELAHERE, which demonstrated an overall survival benefit in a Phase 3 trial for platinum-resistant ovarian cancer. They also presented positive interim analysis results for their therapy Pivekimab Sunirine in BPDCN. The company generated $350.8 million in net proceeds from a public equity offering. Financial results showed total revenues of $83.2 million, with a net loss of $4.2 million for Q2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.71%
Tags
-
Rhea-AI Summary
ImmunoGen to participate in fireside chat at Canaccord Genuity Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
none
Rhea-AI Summary
IMGN: ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem for Novel ADCs. Collaboration combines ImmunoGen's proprietary linker-payload technology with ImmunoBiochem's antibodies directed against specific targets. ImmunoBiochem to receive upfront payment, milestone payments, and tiered royalties. Agreement reinforces ImmunoGen's commitment to pipeline expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
none
Rhea-AI Summary
ImmunoGen to participate in fireside chat at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
Immunogen Inc

Nasdaq:IMGN

IMGN Rankings

IMGN Stock Data

8.72B
278.38M
0.32%
86.52%
7.38%
Biotechnology
Healthcare
Link
United States
Waltham